Neue Suche | Kongressdetail
mail
Druckansicht
 
 

12th Alzheimer's and Parkinson's Drug Development Summit

Evvnt Promotion / evvnt
-
23.04.2024 - 25.04.2024  Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
 
Kongressthemen
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/2146026-3?pid=4832

Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more
 

Anfragen und Anmeldung:

https://go.evvnt.com/2146026-2?pid=4832
Frau Erin Thomas
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
USD 2999.00 - USD 5197.00
Teilnehmer erwartet
1000 - 1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

Hilfswerk AustriaSwiss Tropical and Public Health InstituteAnästhesie in Entwicklungsländern e. V.AMREF - African Medical and Research FoundationÖsterreichisches Rotes KreuzCharité International AcademyCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation